Atsushi Takano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Atsushi Takano has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Yataro Daigo
Department of Medical Oncology, Shiga University of Medical Science, Otsu, Shiga, Japan
5 shared publications Eiju Tsuchiya
3 shared publications- Hideto Oshita3 shared publications
Hirohiko Akiyama
3 shared publications- Masato Aragaki
Department of Thoracic Surgery Hokkaido University Hospital Sapporo Japan
3 shared publications Nobuoki Kohno
3 shared publications
Latest Publications
- 1 September 2026
- Published by AIP Publishing in Biomicrofluidics
- Vol. 20 (5)
Locally addressable pneumatic actuation with embedded soft valves
This paper describes a method to fabricate pneumatic network (pneu-net)-based actuators with embedded soft valves that can be readily integrated for the local control of motions. Soft actuators consisting of pneu-nets of elastomeric chambers have been widely developed, while locally addressable control of motion remains challenging. Integration of valves is beneficial to achieve such controls, although existing methods rely on rigid components that would compromise the local flexibility of the actuators. To address this problem, we designed pneumatic soft valves consisting of elastomeric chambers, microchannels, and a straining layer to realize fully elastomeric actuators. Integration of the soft valves with typical pneu-net actuators was demonstrated via a simple molding process using 3D-printed templates. The embedded soft valves allowed regulating the airflow to the pneu-net to control the mode of actuation without causing undesired deformation. Using the developed principle, we demonstrated two representative devices—soft valve-embedded pneu-net actuators and selectively actuatable pneu-net pads—to showcase multiple modes of deformation based on locally controllable actuation. This is the first report of the fully elastomeric pneu-net actuators whose motions can be controlled by local deformation with the pneumatically controlled soft valves. The concept developed here—integrating fully elastomeric valves into pneu-nets—will contribute to design the motions of soft actuators only with pneumatic input without relying on rigid electronic and mechanical components.
- 1 September 2026
- Published by AIP Publishing in Biomicrofluidics
- Vol. 20 (5)
Locally addressable pneumatic actuation with embedded soft valves
This paper describes a method to fabricate pneumatic network (pneu-net)-based actuators with embedded soft valves that can be readily integrated for the local control of motions. Soft actuators consisting of pneu-nets of elastomeric chambers have been widely developed, while locally addressable control of motion remains challenging. Integration of valves is beneficial to achieve such controls, although existing methods rely on rigid components that would compromise the local flexibility of the actuators. To address this problem, we designed pneumatic soft valves consisting of elastomeric chambers, microchannels, and a straining layer to realize fully elastomeric actuators. Integration of the soft valves with typical pneu-net actuators was demonstrated via a simple molding process using 3D-printed templates. The embedded soft valves allowed regulating the airflow to the pneu-net to control the mode of actuation without causing undesired deformation. Using the developed principle, we demonstrated two representative devices—soft valve-embedded pneu-net actuators and selectively actuatable pneu-net pads—to showcase multiple modes of deformation based on locally controllable actuation. This is the first report of the fully elastomeric pneu-net actuators whose motions can be controlled by local deformation with the pneumatically controlled soft valves. The concept developed here—integrating fully elastomeric valves into pneu-nets—will contribute to design the motions of soft actuators only with pneumatic input without relying on rigid electronic and mechanical components.
- Open Access
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 5846
Abstract 5846: Comprehensive genomics-based screening of novel therapeutic targets and biomarkers for lung cancer
As the number of patients with lung cancer who show good response to standard therapies is limited, new molecular targeted therapies and biotherapies with predictive biomarkers are urgently required. We have been developing molecular therapies targeting oncoproteins with their companion diagnostics as follows, i) To identify overexpressed genes in 120 lung cancers by gene expression microarray analysis of 27,648 genes, ii) To verify the candidate genes for their scarce expression in 23 normal organs, iii) To validate the clinicopathologic significance of their protein expression by tissue microarray covering hundreds of lung cancers including non-small cell lung cancers (NSCLCs), and iv) To examine whether they are important for the growth or invasion of cancer cells by using siRNAs and/or small molecule inhibitors. By this screening system, we identified dozens of candidate target molecules and selected a gene encoding protein with a GAP domain, LAPG1 (lung cancer-associated protein with Gap domain 1). Immunohistochemical analysis showed that LAPG1 expression was observed in 69.9% of lung cancers. Moreover positivity of LAPG1 expression was associated with poor prognosis for lung cancer patients. Knockdown of LAPG1 expression by siRNAs suppressed growth of lung cancer cells. Introduction of LAPG1 increased the invasive activity of mammalian cells, indicating that LAPG1 could be a prognostic biomarker and therapeutic target for lung cancers. Our comprehensive genomics-based screening might be useful to select the novel biomarkers and therapeutic targets for developing small molecules, antibodies, nucleic acid drugs, and immunotherapies against lung cancer. Citation Format: Yataro Daigo, Atsushi Takano, Yusuke Nakamura. Comprehensive genomics-based screening of novel therapeutic targets and biomarkers for lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5846.
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 5846
Open AccessAbstract 5846: Comprehensive genomics-based screening of novel therapeutic targets and biomarkers for lung cancer
As the number of patients with lung cancer who show good response to standard therapies is limited, new molecular targeted therapies and biotherapies with predictive biomarkers are urgently required. We have been developing molecular therapies targeting oncoproteins with their companion diagnostics as follows, i) To identify overexpressed genes in 120 lung cancers by gene expression microarray analysis of 27,648 genes, ii) To verify the candidate genes for their scarce expression in 23 normal organs, iii) To validate the clinicopathologic significance of their protein expression by tissue microarray covering hundreds of lung cancers including non-small cell lung cancers (NSCLCs), and iv) To examine whether they are important for the growth or invasion of cancer cells by using siRNAs and/or small molecule inhibitors. By this screening system, we identified dozens of candidate target molecules and selected a gene encoding protein with a GAP domain, LAPG1 (lung cancer-associated protein with Gap domain 1). Immunohistochemical analysis showed that LAPG1 expression was observed in 69.9% of lung cancers. Moreover positivity of LAPG1 expression was associated with poor prognosis for lung cancer patients. Knockdown of LAPG1 expression by siRNAs suppressed growth of lung cancer cells. Introduction of LAPG1 increased the invasive activity of mammalian cells, indicating that LAPG1 could be a prognostic biomarker and therapeutic target for lung cancers. Our comprehensive genomics-based screening might be useful to select the novel biomarkers and therapeutic targets for developing small molecules, antibodies, nucleic acid drugs, and immunotherapies against lung cancer. Citation Format: Yataro Daigo, Atsushi Takano, Yusuke Nakamura. Comprehensive genomics-based screening of novel therapeutic targets and biomarkers for lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5846.
- Open Access
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 5664
Abstract 5664: Characterization of OASEP1 as a biomarker and therapeutic target for oral cancer
This study aims to identify new biomarkers and therapeutic targets for oral cancer. Our strategies are as follows: i) Identification of overexpressed genes in oral cancers by gene expression array analysis, ii) Validation of clinicopathologic significance of their protein expression by tissue microarray, iii) Examination of their growth effect on cancer cell by siRNAs. We identified a secreted protein, OASEP1 (oral cancer-associated serum protein 1) as a candidate. Immunohistochemical staining showed that OASEP1 protein expression was observed in 120 (75.4%) of 159 oral cancers that had undergone curative surgery. High level of OASEP1 expression was associated with poor prognosis for oral cancer patients (P = 0.0054, by log-rank test). Multivariate analysis revealed that strong OASEP1 expression was an independent prognostic factor. Suppression of OASEP1 expression by siRNA specific for OASEP1 significantly inhibited the growth of oral cancer cell lines through apoptosis as detected by apoptosis assays and time lapse imaging. In addition, siRNAs for the receptor of OASEP1 also significantly inhibited the growth of oral cancer cells. Enforced OASEP1 expression significantly enhanced the growth of cancer cells. Addition of OASEP1 protein significantly increased the growth of oral cancer cells in a dose dependent manner, suggesting that the interaction between OASEP1 and its receptor regulated the growth of oral cancer cells. Microarray analysis coupled with siRNAs for OASEP1 demonstrated various OASEP1-related oncogenic pathways in oral cancer cells. Our data suggest that OASEP1 is a possible prognostic biomarker and therapeutic target for oral cancer. Citation Format: Atsushi Takano, Yoshihiro Yoshitake, Masanori Shinohara, Yataro Daigo. Characterization of OASEP1 as a biomarker and therapeutic target for oral cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5664.
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 5664
Open AccessAbstract 5664: Characterization of OASEP1 as a biomarker and therapeutic target for oral cancer
This study aims to identify new biomarkers and therapeutic targets for oral cancer. Our strategies are as follows: i) Identification of overexpressed genes in oral cancers by gene expression array analysis, ii) Validation of clinicopathologic significance of their protein expression by tissue microarray, iii) Examination of their growth effect on cancer cell by siRNAs. We identified a secreted protein, OASEP1 (oral cancer-associated serum protein 1) as a candidate. Immunohistochemical staining showed that OASEP1 protein expression was observed in 120 (75.4%) of 159 oral cancers that had undergone curative surgery. High level of OASEP1 expression was associated with poor prognosis for oral cancer patients (P = 0.0054, by log-rank test). Multivariate analysis revealed that strong OASEP1 expression was an independent prognostic factor. Suppression of OASEP1 expression by siRNA specific for OASEP1 significantly inhibited the growth of oral cancer cell lines through apoptosis as detected by apoptosis assays and time lapse imaging. In addition, siRNAs for the receptor of OASEP1 also significantly inhibited the growth of oral cancer cells. Enforced OASEP1 expression significantly enhanced the growth of cancer cells. Addition of OASEP1 protein significantly increased the growth of oral cancer cells in a dose dependent manner, suggesting that the interaction between OASEP1 and its receptor regulated the growth of oral cancer cells. Microarray analysis coupled with siRNAs for OASEP1 demonstrated various OASEP1-related oncogenic pathways in oral cancer cells. Our data suggest that OASEP1 is a possible prognostic biomarker and therapeutic target for oral cancer. Citation Format: Atsushi Takano, Yoshihiro Yoshitake, Masanori Shinohara, Yataro Daigo. Characterization of OASEP1 as a biomarker and therapeutic target for oral cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5664.
- 1 November 2014
- Published by AIP Publishing in Biomicrofluidics
- Vol. 8 (6) , 061101
On-chip multi-gas incubation for microfluidic cell cultures under hypoxia
We developed a simple system that regulates CO2 and O2 levels within a microfluidic chip. This system enables long-term cell culture under hypoxic conditions without the need of a CO2 incubator or a multi-gas incubator. Hypoxic conditions were generated using a miniature water jacket containing dissolved ascorbate as an oxygen scavenger. Formulations of the water jacket were determined that enables both 5% pCO2 and desired pO2 levels ranging from 5 to 15%. We also cultured PC-12 cells and primary neuronal cells from chick embryos under hypoxia and observed hypoxia-induced cell death and inhibition of neurite outgrowth.
- 1 November 2014
- Published by AIP Publishing in Biomicrofluidics
- Vol. 8 (6) , 061101
On-chip multi-gas incubation for microfluidic cell cultures under hypoxia
We developed a simple system that regulates CO2 and O2 levels within a microfluidic chip. This system enables long-term cell culture under hypoxic conditions without the need of a CO2 incubator or a multi-gas incubator. Hypoxic conditions were generated using a miniature water jacket containing dissolved ascorbate as an oxygen scavenger. Formulations of the water jacket were determined that enables both 5% pCO2 and desired pO2 levels ranging from 5 to 15%. We also cultured PC-12 cells and primary neuronal cells from chick embryos under hypoxia and observed hypoxia-induced cell death and inhibition of neurite outgrowth.